Skip to main content
OpenTrials
Completed

NCT Number: NCT03601429

Dietary Supplementation of Lactogyn in Women With Bacterial Vaginosis

The objective of the study is to determine clinical efficacy of Lactogyn (Lactobacillus Crispatus, L. brevis, L.acidophilus) in prevention of recurrent BV

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Sergiy V. Gerasymov, MD, PhD

Lviv, 79049, Ukraine

About this study

According to classification, this is a phase 2 randomized parallel group prospective controlled dietary study to evaluate efficacy of a dietary supplement, a combination of L. crispatus LMG S-29995, L. brevis, and L. acidophilus in women aged from 18 through 45 years suffering from rBV. The 2 phase of the study has been ascribed as there is no evidence that oral capsules with L. crispatus LMG S-29995, L. brevis, and L. acidophilus have a potential efficacy in rBV.

Qualifying women received a combination of the three probiotic strains with a half daily recommended dose of vitamin C or just vitamin C without probiotics, a control supplementation, via oral route of administration for up to 120 days. During the intake of active or control formulations, participants kept a structured 120-DSD, where they recorded test capsules intake, screen for symptoms of bacterial vaginosis, and food intolerance events.

Based on repeat physical examination with application of Amsel and Nugent criteria the main conclusions over the efficacy of probiotic strains were made.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent form signed;
  • Age: 18-45 years;
  • Able to swallow capsules;
  • Recent symptomatic BV successfully treated with metronidazole tablets in a dose of 500 mg 2 times daily for 7 days;
  • Less than 48 hours after treatment of acute BV defined as three out of four Amsel criteria;
  • Willing to communicate intimate history for the study purposes;
  • Consent not to use spermicides for 4 months after starting TDC;
  • Stated availability throughout the study period and a mobile phone.

Exclusion criteria

  • Post-menopausal;
  • Pregnancy or high risk of;
  • Breast feeding;
  • Currently active STD as determined by history, physical examination, and laboratory tests;
  • Diabetes mellitus;
  • Inflammatory bowel disease;
  • Alcohol or drug addiction as guessed by investigator;
  • Absence of refrigerator;
  • Known moderate to severe disease of any systems;
  • Difficulty to comprehend study requirements as judged by physician;
  • Any erosions, herpes like lesions, cervicitis during vaginal examination;
  • Treatment of BV with other than metronidazole antibiotic;
  • Use of any investigational drug within the previous 30 days;
  • Use of drugs that suppress the immune system.

Treatment and study plan

Lactogyn

Dietary Supplement

capsules

Placebo

Dietary Supplement

capsules

Primary outcomes

  1. Percent change in recurrence of BV during Lactogyn supplementation

    Time frame: 4 months

    Percent change in recurrence of BV during the 4 months of dietary supplementation

Sponsors and collaborators

Lead sponsor

Vesale Pharmaceutica

Industry

Registry information

Official study title

Dietary Supplementation of Lactogyn in Women With Bacterial Vaginosis: a Randomized Clinical Trial

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Jul 26, 2018
Registry last updated
Apr 29, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.